News|Articles|October 31, 2024
WCG Randomized 1,600 Participants for RSV Vaccine Trial
Author(s)WCG Clinical
A top 5 sponsor turned to WCG to recruit expecting mothers for its Phase III RSV vaccine trial. WCG support covered multiple countries and contributed almost one third of overall randomizations in the supported countries, bringing the study in ahead of schedule despite delays due to COVID-19 impacts on RSV seasonality. The sponsor met study timeline past enrollment by continuing to work with WCG’s retention support.
Trending on Applied Clinical Trials Online
1
When the Slack Runs Out: AI and the CRO Operating Model
2
Why Site Payment Inconsistency Has Persisted for So Long
3
Why Payment Performance Has Become a Competitive Differentiator for Sponsors
4
Speed, Discipline, and the New Rules of Biotech Development: Q&A with Stella K. Vnook, PhD, Kaida BioPharma and Aviva Ventures
5